MIRM
Mirum Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +6.2% ·
share flow -0.3% ·
net new positions +5.9%
· formula
Ownership fragmentation: more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 105 | +1 | 35.65M | $4.17B | +8 | −7 |
| Q1 2026 | 107 | +6 | 39.52M | $3.63B | +12 | −7 |
| Q4 2025 | 102 | +1 | 36.05M | $2.83B | +2 | n/a |
| Q3 2025 | 20 | 0 | 17.64M | $1.29B | n/a | n/a |
| Q2 2025 | 17 | +1 | 13.61M | $692.65M | +2 | −1 |
| Q1 2025 | 13 | +1 | 7.45M | $335.67M | +2 | −1 |
| Q4 2024 | 12 | 0 | 6.63M | $274.04M | +1 | −1 |
| Q3 2024 | 11 | +2 | 4.84M | $188.84M | +2 | n/a |
| Q2 2024 | 9 | n/a | 4.39M | $149.94M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 3.58M | n/a | $182.04M | 0.0% | n/c | 1 | SEC ↗ ×14 |
| 2 | The Vanguard Group ✦ (passive) | 2.56M | n/a | $130.53M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 3 | T. Rowe Price ✦ | 1.42M | +0.1% | $72.12M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 4 | Citadel Advisors ✦ | 1.41M | -2.7% | $71.57M | 0.1% | ▼ Trim | 5 | SEC ↗ ×3 |
| 5 | State Street Global Advisors ✦ (passive) | 1.38M | -8.0% | $70.01M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 1.03M | +6.8% | $52.40M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 7 | D. E. Shaw & Co. ✦ | 554.96K | +2.1% | $28.24M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 8 | Renaissance Technologies ✦ | 396.35K | +110.3% | $20.17M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | Millennium Management ✦ | 288.16K | -39.9% | $14.66M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 10 | Point72 Asset Management ✦ | 258.87K | +11.5% | $13.17M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 11 | Adage Capital Partners ✦ | 243.00K | -29.6% | $12.37M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 12 | Two Sigma Investments ✦ | 171.81K | -1.9% | $8.74M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 13 | Wellington Management ✦ | 118.57K | +5.0% | $6.03M | 0.0% | ▲ Add | 5 | SEC ↗ ×5 |
| 14 | Arrowstreet Capital ✦ | 75.64K | New | $3.85M | 0.0% | New | 1 | SEC ↗ |
| 15 | Fidelity (FMR) ✦ | 59.44K | n/a | $3.02M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 16 | AQR Capital Management ✦ | 47.52K | -3.2% | $2.42M | 0.0% | ▼ Trim | 5 | SEC ↗ ×4 |
| 17 | Marshall Wace ✦ | 25.54K | New | $1.30M | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Arrowstreet Capital | $3.85M | 0.0% |
| Marshall Wace | $1.30M | 0.0% |
Exited
| Gotham Asset Management | $272,237 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 308 holders, 67.83M shares, $6.01B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 9.94K sh · $978,093
Officer · 658 sh · $65,800
Officer · 40.00K sh · $4.00M
Officer · 6.00K sh · $599,510
Officer, Director · 2.30K sh · $230,322
Officer, Director · 6.02K sh · $597,187
Officer, Director · 11.68K sh · $1.15M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology